Genmab A/S Files June 2024 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Genmab filed its June 6-K, check for updates.
AI Summary
Genmab A/S filed a Form 6-K on June 27, 2024, to report information for the month of June 2024. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File No. 333-277273.
Why It Matters
This filing serves as an update for investors and indicates ongoing reporting requirements for Genmab A/S, potentially including material information relevant to its stock.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign private issuers and typically contains updates or information that doesn't represent a significant new event.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009528 (filing_id) — Accession Number
- 20240627 (date) — Filing Date
- 333-232693 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-253519 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-262970 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-277273 (registration_statement_id) — Incorporated by reference in S-8 registration statement
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information to the SEC that the issuer makes or is required to make public in its home country.
When was this specific Form 6-K filed?
This Form 6-K was filed on June 27, 2024.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Numbers 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address for Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
What is the SIC code for Genmab A/S?
The Standard Industrial Classification (SIC) code for Genmab A/S is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-06-27 10:02:34
Filing Documents
- tmb-20240627x6k.htm (6-K) — 18KB
- tmb-20240627xex99d1.htm (EX-99.1) — 82KB
- tmb-20240627xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009528.txt ( ) — 108KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: June 27, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated June 27, 2024: EPKINLY (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)